Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REP 2055
- Development stage
- Phase 2
- Lead developer
- Replicor
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
REP 2055 is a nucleic acid polymer (NAP), specifically a synthetic, amphipathic, oligonucleotide composed of polycytidine and approximately 40 nucleotides in length. It was developed as an antiviral agent targeting hepatitis B virus (HBV) and has also shown activity against hepatitis C virus (HCV) and duck hepatitis B virus (DHBV). Its primary mechanism is to inhibit the release of hepatitis B surface antigen (HBsAg) from infected hepatocytes, which is believed to help restore immune control over chronic HBV infection. Unlike some other NAPs, it does not contain CpG motifs and does not directly stimulate the immune system. In preclinical models and early clinical studies, it demonstrated both prophylactic and therapeutic effects by reducing viral markers in serum and promoting sustained virologic responses after treatment cessation[1][2][3][5][6].
- Other names
- REP 2055REP2055REP-2055REP 9ACREP9ACREP-9AC
02
Targets
DNAJB12 (DnaJ heat shock protein family member B12)
Beyond the preview
Go deeper on REP 2055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REP 2055.